These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37776767)

  • 1. Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity.
    Jiang X; Liu J; Lee MJ; Peng C; Luo T; Tillman L; Weichselbaum RR; Lin W
    Biomaterials; 2023 Nov; 302():122334. PubMed ID: 37776767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors.
    Lee JH; Song J; Kim IG; You G; Kim H; Ahn JH; Mok H
    Acta Biomater; 2022 Mar; 141():354-363. PubMed ID: 35007784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-Loaded Squalene Emulsion.
    Zhang Z; Kuo JC; Zhang C; Huang Y; Lee RJ
    J Pharm Sci; 2022 Nov; 111(11):3038-3046. PubMed ID: 35697319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-adjuvanting photosensitizer nanoparticles for combination photodynamic immunotherapy.
    Zhang G; Wang N; Sun H; Fu X; Zhai S; Cui J
    Biomater Sci; 2021 Oct; 9(20):6940-6949. PubMed ID: 34528658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
    Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
    Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity.
    Yan J; Zhang Y; Du S; Hou X; Li W; Zeng C; Zhang C; Cheng J; Deng B; McComb DW; Zhao W; Xue Y; Kang DD; Cheng X; Dong Y
    Adv Mater; 2022 Nov; 34(47):e2207486. PubMed ID: 36121735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer.
    Xu J; Xu L; Wang C; Yang R; Zhuang Q; Han X; Dong Z; Zhu W; Peng R; Liu Z
    ACS Nano; 2017 May; 11(5):4463-4474. PubMed ID: 28362496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response.
    Zhu X; Wang X; Li B; Zhang Y; Chen Y; Zhang W; Wang Y; Zhai W; Liu Z; Liu S; Sun J; Chen Z; Gao Y
    Small; 2022 May; 18(20):e2107001. PubMed ID: 35434938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
    Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
    Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
    Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Intelligent Nanovehicle Armed with Multifunctional Navigation for Precise Delivery of Toll-Like Receptor 7/8 Agonist and Immunogenic Cell Death Amplifiers to Eliminate Solid Tumors and Trigger Durable Antitumor Immunity.
    Hao Y; Li H; Zhao H; Liu Y; Ge X; Li X; Chen H; Yang A; Zou J; Li X; Sun X; Zhang X; Wang X; Li Z; Zhang Q; Wu H; Wang G; Zhang J; De Geest BG; Zhang Z
    Adv Healthc Mater; 2022 Jun; 11(12):e2102739. PubMed ID: 35306756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
    van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
    Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.